Twist Bioscience reported first-quarter sales of $103.7 million, marking a 17% increase year-over-year and surpassing both the Street consensus of $102.72 million and the company’s own guidance range of $100 million to $101 million. The company delivered a net loss of $0.50 per share, in line with analyst expectations. Management highlighted continued customer expansion, new product launches, and gross margins maintained above 50% as key drivers of performance.

Building on the first-quarter results, Twist Bioscience increased its full-year revenue outlook to a range of $435 million to $440 million from prior guidance of $425 million to $435 million. This new target exceeds the consensus forecast of $431.39 million and reflects expected balanced growth across both the company’s DNA synthesis (DSPs) and next-generation sequencing (NGS) businesses. Management reiterated its goal of achieving gross margins above 52% and adjusted EBITDA breakeven by the fourth quarter of fiscal 2026.

Following the earnings release, Barclays’ Luke Sergott maintained an Overweight rating on Twist Bioscience and raised his price target from $39 to $50, citing the stronger-than-expected revenue trajectory and margin expansion potential. Evercore ISI’s Vijay Kumar kept an Outperform rating and lifted his target from $42 to $52, pointing to the company’s scalable platform and accelerating product adoption across research and industrial markets.

CEO Emily Leproust emphasized the company’s commitment to disciplined spending in pursuit of sustainable, profitable growth. Initiatives include leveraging AI-driven design tools to accelerate customer workflows, expanding the addressable market through strategic partnerships, and scaling operations to support higher throughput. Management’s discipline around R&D investment and operational efficiency is designed to drive adjusted EBITDA breakeven and further improve gross margins over the remainder of fiscal 2026.